Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001461 · ClinicalTrials.gov registry record

Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme

A clinical trial of Atherosclerosis and Coronary Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
209
Enrollment target
1
Study location

NCT00001461 is a study of Atherosclerosis and Coronary Disease that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 209 participants, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001461, a study of Atherosclerosis and Coronary Disease, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
209 participants
Enrollment target
1
Study location

Study Summary

The walls of blood vessels are lined by flat cells that are responsible for releasing substance(s) that control the activity of the blood vessel. These cells are referred to as the endothelium of the blood vessel. One of the substances released from the endothelium is called nitric oxide (NO). This substance functions to keep blood vessels relaxed and to prevent blood from clotting inside the vessels. Studies done by researchers in the Cardiology Branch of the National Heart, Lung and Blood Institute have shown that nitric oxide activity may be lower in patients with hardening of the arteries (atherosclerosis) and risk factors for atherosclerosis. Another substance released by the cells of the endothelium is called bradykinin. It functions to stimulate the production of nitric oxide. Therefore bradykinin is also responsible for the relaxation and widening of blood vessels. An enzyme found in the blood called angiotensin-converting enzyme (ACE) inactivates baradykinin and thereby decreases the production of nitric oxide. The activity of ACE is determined by genetics and is different in each person. Medications that block ACE (ACE-inhibitors) may be useful for patients with high levels of ACE activity. This study is designed to determine; 1. The role of bradkinin in stimulating the production of nitric oxide 2. Whether ACE-inhibitors improve blood vessel relaxation caused by bradykinin 3. Whether ACE-inhibitors improve abnormal blood vessel relaxation 4. Whether ACE-inhibitors and bradykinin affect blood clotting 5. Whether blood vessel response to ACE-inhibitor and bradykinin depends on the patients genetic make-up

Study Locations (1)

Maryland

  • National Heart, Lung and Blood Institute (NHLBI) - Bethesda

Trial Details

FieldValue
Enrollment Target 209 participants
Start Date 1995-03
Est. Completion 2001-04

What the Registry Record Tells You About NCT00001461

The ClinicalTrials.gov registry entry for NCT00001461 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (80% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT00001461 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00001461 about?

NCT00001461 is a clinical study titled "Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme". The walls of blood vessels are lined by flat cells that are responsible for releasing substance(s) that control the activity of the blood vessel. These cells are referred to as the endothelium of the blood vessel. One of the substances released from the endothelium is called nitric oxide (NO). This ...

What is the current status of trial NCT00001461?

This trial is currently completed. The enrollment target is 209 participants. The study started on 1995-03. Estimated completion is 2001-04.

What conditions does trial NCT00001461 study?

This clinical trial studies the following conditions: Atherosclerosis, Coronary Disease.

Who is sponsoring clinical trial NCT00001461?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001461 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atherosclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.